Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis
Пероральные антикоагулянты для профилактики инсульта при фибрилляции предсердий: систематический обзор, сетевой метаанализ и анализ экономической эффективности
2017-11-28
SCID: 54.1/wdaq5c8y
Discuss with AI
atrial fibrillationcost-effectiveness analysisdirect oral anticoagulantsnetwork meta-analysisstroke prevention
Figures from the paper
Abstract (AI)
Abstract Objective To compare the efficacy, safety, and cost effectiveness of direct acting oral anticoagulants (DOACs) for patients with atrial fibrillation. Design Systematic review, network meta-analysis, and cost effectiveness analysis. Data sources Medline, PreMedline, Embase, and The Cochrane Library. Eligibility criteria for selecting studies Published randomised trials evaluating the use of a DOAC, vitamin K antagonist, or antiplatelet drug for prevention of stroke in patients with atrial fibrillation. Results 23 randomised trials involving 94 656 patients were analysed: 13 compared a DOAC with warfarin dosed to achieve a target INR of 2.0-3.0. Apixaban 5 mg twice daily (odds ratio 0.79, 95% confidence interval 0.66 to 0.94), dabigatran 150 mg twice daily (0.65, 0.52 to 0.81), edoxaban 60 mg once daily (0.86, 0.74 to 1.01), and rivaroxaban 20 mg once daily (0.88, 0.74 to 1.03) reduced the risk of stroke or systemic embolism compared with warfarin. The risk of stroke or systemic embolism was higher with edoxaban 60 mg once daily (1.33, 1.02 to 1.75) and rivaroxaban 20 mg once daily (1.35, 1.03 to 1.78) than with dabigatran 150 mg twice daily. The risk of all-cause mortality was lower with all DOACs than with warfarin. Apixaban 5 mg twice daily (0.71, 0.61 to 0.81), dabigatran 110 mg twice daily (0.80, 0.69 to 0.93), edoxaban 30 mg once daily (0.46, 0.40 to 0.54), and edoxaban 60 mg once daily (0.78, 0.69 to 0.90) reduced the risk of major bleeding compared with warfarin. The risk of major bleeding was higher with dabigatran 150 mg twice daily than apixaban 5 mg twice daily (1.33, 1.09 to 1.62), rivaroxaban 20 mg twice daily than apixaban 5 mg twice daily (1.45, 1.19 to 1.78), and rivaroxaban 20 mg twice daily than edoxaban 60 mg once daily (1.31, 1.07 to 1.59). The risk of intracranial bleeding was substantially lower for most DOACs compared with warfarin, whereas the risk of gastrointestinal bleeding was higher with some DOACs than warfarin. Apixaban 5 mg twice daily was ranked the highest for most outcomes, and was cost effective compared with warfarin. Conclusions The network meta-analysis informs the choice of DOACs for prevention of stroke in patients with atrial fibrillation. Several DOACs are of net benefit compared with warfarin. A trial directly comparing DOACs would overcome the need for indirect comparisons to be made through network meta-analysis. Systematic review registration PROSPERO CRD 42013005324.
Key Findings
1
A systematic review and network meta-analysis included 23 randomized trials involving 94,656 patients with atrial fibrillation.
2
All evaluated DOACs reduced all-cause mortality compared with warfarin.
3
Apixaban, dabigatran 110 mg, and edoxaban doses reduced major bleeding versus warfarin; most DOACs lowered intracranial bleeding but some increased gastrointestinal bleeding.
4
Compared with warfarin, apixaban 5 mg twice daily and dabigatran 150 mg twice daily significantly reduced stroke or systemic embolism risk; edoxaban 60 mg and rivaroxaban 20 mg showed numerically lower risks.
5
Edoxaban 60 mg and rivaroxaban 20 mg had higher stroke or systemic embolism risks than dabigatran 150 mg twice daily.
Research Object
Direct acting oral anticoagulants for patients with atrial fibrillation
Research Subject
Comparative efficacy, safety, and cost effectiveness for preventing stroke and systemic embolism
Publication Details
Publication Date
2017-11-28
Journal
Publisher
ISSN
Cited by
580
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai1
Cited by4
2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines2023
Action Plan for Stroke in Europe 2018–20302018
Ischemic Stroke despite Oral Anticoagulant Therapy in Patients with Atrial Fibrillation2020
Low-Intensity Monitoring for Mild-to-Moderate Acute Ischemic Stroke Is Cost Saving: Economic Evaluation for OPTIMISTmain2026